This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Johnson, M. Search for Related Content PubMed PubMed Citation Articles by Johnson, M. Social Bookmarking                         What's this?

Problems of anticoagulation within a palliative care setting: an audit of hospice patients taking warfarin

Huntershill Marie Curie Centre, Belmont Road, Glasgow

Patients with cancer have an increased risk of venous thromboembolism (VTE) compared with a healthy population. The risk increases as cancer progresses and this is reflected in the number of hospice inpatients with VTE. These patients also have an increased risk of bleeding due to tumour site, complications of treatment, progressive liver involvement and concurrent medication such as nonsteroidal anti-inflammatory agents. Therefore anticoagulation of cancer patients with VTE is fraught with difficulty. This audit of hospice inpatients taking warfarin showed a high incidence of bleeding which was possibly improved with very stringent international normalized ratio (INR) monitoring: 15 episodes in 17 patients improved to 11 episodes in 18 patients. Patient numbers were small and the two groups heterogeneous, thus formal statistical analysis could not be applied. One patient in each group continued to thrombose despite overanticoagulation with warfarin. Monitoring of INR increased from an average of once every six days to once every 2.4 days. Such frequent monitoring is likely to be highly impractical in many hospice and general practice settings. Control of warfarin as measured by average percentage of INRs in, above or below the therapeutic range if anything appeared to be worse in the second group. Any bleeding in these patients was distressing. As a result of this audit, practice in Huntershill Marie Curie Centre has changed. Low molecular weight heparins are proven to be efficacious in the treatment of VTE, are renally excreted and therefore do not interact with many commonly used concurrent medications. They can be administered once daily and do not need monitoring of anticoagulant effect. Thus they will be used in patients for whom anticoagulation is indicated during a six-month period, after which practice will be again reviewed.

Key Words: neoplasms • palliative care • thromboembolism • warfarin

Palliative Medicine, Vol. 11, No. 4, 306-312 (1997)
DOI: 10.1177/026921639701100407


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S Noble The challenges of managing cancer related venous thromboembolism in the palliative care setting Postgrad. Med. J., November 1, 2007; 83(985): 671 - 674. [Abstract] [Full Text] [PDF]

				S.I.R. Noble, K. Hood, and I.G. Finlay The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patients Palliative Medicine, September 1, 2007; 21(6): 473 - 476. [Abstract] [PDF]

				S. I. Noble and I G Finlay Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study Palliative Medicine, April 1, 2005; 19(3): 197 - 201. [Abstract] [PDF]

				J. Kirkova, D. Oneschuk, and J. Hanson Deep vein thrombosis (DVT) in advanced cancer patients with lower extremity edema referred for assessment American Journal of Hospice and Palliative Medicine, March 1, 2005; 22(2): 145 - 149. [Abstract] [PDF]

				J. Pereira and T. Phan Management of Bleeding in Patients with Advanced Cancer Oncologist, September 1, 2004; 9(5): 561 - 570. [Abstract] [Full Text] [PDF]

				M J Johnson Problems of anticoagulation within a palliative care setting - correction Palliative Medicine, September 1, 1998; 12(6): 463 - 463. [PDF]